Search bioRxiv⌕ Search

Biology subjects

Venneker, S.

Publications and source records attributed to Venneker, S..

2 recordsLinked to original sources

Immune infiltration is linked to increased transcriptional activity and distinct metabolic profiles in chordomas

Chordomas are ultra-rare cancers from the axial skeleton with limited treatment options. Chordomas can exhibit immunogenic features, and immune checkpoint blockade has demonstrated clinical activity in some patients, yet the determinants of these responses remain poorly understood. We aimed to elucidate the biological basis of immunogenicity in chordomas through spatial transcriptomic and metabolomic analyses. We applied GeoMx digital spatial profiling to 15 chordomas, analyzing tumor and stromal compartments separately and comparing inflamed and non-inflamed tumors. Consecutive tissue sections were examined using MALDI-mass spectrometry imaging (MSI) at 20 {micro}m spatial resolution. Findings were further explored through immunohistochemistry analyses. To assess whether transcriptional activity in tumor cells was associated with interferon-{gamma} (IFN-{gamma}) signaling, we tested the effect of IFN-{gamma} treatment on chordoma cell lines. Digital spatial profiling of inflamed and non-inflamed chordomas revealed striking differences in both the cancer cell and stromal compartments. Increased immune infiltration was strongly associated with elevated transcriptional activity in cancer cells. MALDI-MSI revealed distinct metabolic signatures and pronounced glycogen accumulation in inflamed chordomas. Nevertheless, IFN-{gamma} stimulation of chordoma cell lines did not induce expression of TBXT (brachyury), the master transcriptional regulator of chordoma biology. Collectively, our findings reveal a strong association between the transcriptomic and metabolic activity in chordomas and their immunogenicity. However, the causal direction of this relationship remains to be determined. Nevertheless, these findings are highly relevant for patient stratification, particularly in the context of immunotherapeutic strategies.

cancer biology↗

DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomas

Somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at high frequency in several tumour types. Even though these mutations are confined to distinct hotspots, we show that gliomas are the only tumour type with an exceptionally high percentage of IDH1R132H mutations. This high prevalence is important as IDH1R132H is presumed to be relatively poor at producing D-2-hydroxyglutarate (D-2HG) whereas high concentrations of this oncometabolite are required to inhibit TET2 DNA demethylating enzymes. Indeed, patients harbouring IDH1R132H mutated tumours have lower levels of genome-wide DNA-methylation, and an associated increased gene expression, compared to tumours with other IDH1/2 mutations ("non-R132H mutations"). This reduced methylation is seen in multiple tumour types and thus appears independent of site of origin. For 1p/19q non-codeleted glioma patients, we show that this difference is clinically relevant: in samples of the randomised phase III CATNON trial, patients harbouring non-R132H mutated tumours have better outcome (HR 0.41, 95% CI [0.24, 0.71], p=0.0013). Non-R132H mutated tumours also had a significantly lower proportion of tumours assigned to prognostically poor DNA-methylation classes (p<0.001). IDH mutation-type was independent in a multivariable model containing known clinical and molecular prognostic factors. To confirm these observations, we validated the prognostic effect of IDH mutation type on a large independent dataset. The observation that non-R132H mutated 1p/19q non-codeleted gliomas have a more favourable prognosis than their IDH1R132H mutated counterpart is clinically relevant and should be taken into account for patient prognostication. Single sentence summaryAstrocytoma patients with tumours harbouring IDH mutations other than p.R132H have increased DNA methylation levels and longer survival

cancer biology↗